by Elec23 | Jun 18, 2026 | News&events, VisMederi
VisMederi and CEVAC, a Belgian vaccine research center comprising a Clinical Trial Unit and an Immunomonitoring Laboratory, have signed a Memorandum of Understanding (MoU) to strengthen their collaboration in vaccine clinical trials, a core area of expertise for both...
by Elec23 | Feb 24, 2025 | News&events
VisMederi has expanded its testing portfolio with cutting-edge pseudo-viral platforms, which are critical tools for examining immunogenicity and developing vaccines against emerging infections. These new technologies enable us to test immune responses in a safe and...
by Elec23 | Feb 4, 2025 | News&events
VisMederi Group believes that successful studies are founded on good partnerships. We are happy to work with Bioclass, Unitech, and Accurange, three firms that play critical roles in supporting our operations and growth. Bioclass is a reliable partner for consulting,...
by Elec23 | Dec 23, 2024 | News&events
On behalf of VisMederi, we are thrilled to share the exciting news about the grand opening of our new Biotech Research Facility in Colle Val d’Elsa. This momentous event, held on December 13th, marked a significant leap forward for our organization, reinforcing our...
by Elec23 | May 10, 2024 | News&events
VisMederi and the International Vaccine Institute have formed a new partnership to accelerate vaccine development in developing countries. VisMederi, a company at the forefront of research and innovation in the life sciences and biotechnology sectors, is pleased to...